Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

CTNM Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $79K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $19.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$79K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How CTNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
CTNM Competitors
Cost of Revenue for CTNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$5.01M USD———
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1M USD+7.4%+307.8%5.0%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$574K USD+69.3%+0.2%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$284K USD+67.1%+24.6%—
GHRSGH Research PLCLTM Mar 2026$268K USD———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$82K USD———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$79K USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding CTNM) —+67.1%+24.6%2.5%

Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050M00
Cost of Revenue000258K0
Gross Profit0050M(258K)0
Gross Margin——100.0%——
Research & Development22.36M16.89M27.6M38.16M51.52M
Selling, General & Admin6.29M5.83M6.32M12.47M16.54M
Operating Expenses28.65M22.72M66.08M50.64M68.06M
Depreciation & Amortization325K329K195K258K323K
EBITDA(28.34M)(23.54M)23.57M(42M)(59.66M)
EBITDA Margin——47.1%——
Operating Income(28.65M)(22.72M)(16.08M)(50.89M)(68.06M)
Operating Margin——-32.2%——
Interest Income77K761K4.61M8.91M8.25M
Interest Expense332K388K208K00
Other Income / Expenses(354K)(1.53M)39.25M8.64M8.08M
Income Before Tax(29M)(24.25M)23.17M(42.26M)(59.98M)
Pre-Tax Margin——46.3%——
Income Tax Expense00450K00
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Net Margin——45.4%——
EPS (Basic)(1.15)(0.97)0.13(1.63)(2.17)
EPS (Diluted)(1.15)(0.97)0.13(1.63)(2.17)
Weighted Avg Shares25.13M25.13M25.13M25.85M27.7M
Weighted Avg Shares (Diluted)25.13M25.13M25.13M25.85M27.7M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Intrinsic Alpha fair value

Locked

Current Price

$9.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.